Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.
Donato F et al. Expert Opin Biol Ther. 2014 Apr 21. [Epub ahead of print].
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
Yee AJ et al. Br J Haematol. 2014 Apr 25. doi: 10.1111/bjh.12909. [Epub ahead of print].
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
Siegel DS et al. Blood Cancer J. 2014 Apr 11;4:e202. doi: 10.1038/bcj.2014.23.
Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.
Robak T et al. Expert Opin Investig Drugs. 2014 Apr 7. [Epub ahead of print].
